Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Positive first-cohort results for ENTR-601-45 in Phase 1/2 ELEVATE-45-201 study.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive first-cohort results for ENTR-601-45 in Phase 1/2 ELEVATE-45-201 study
- Clinical program targets Duchenne muscular dystrophy, a key development milestone for Entrada
- Press release dated October 14, 2026, contains the detailed efficacy and safety findings
Item 8.01 · Other Events
- Cohort 1 showed dystrophin increase of 0.10% versus placebo decline of 0.02%, supporting biological activity at 5 mg/kg
- Exon skipping rose 0.15% versus placebo decline of 0.04%, strengthening ENTR-601-45’s mechanistic evidence
- Favorable 5 mg/kg safety, with no discontinuations, renal concerns, or hypomagnesemia; one participant had resolved serious events
- No functional benefit after three doses, leaving clinical efficacy dependent on higher doses and longer treatment
- Cohort 2 enrollment complete at 10 mg/kg, with data expected in first half of 2027; Cohort 3 may reach 15 mg/kg
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.